ELEV News and Press, Elevation Oncology Inc. From 01/05/24

2024-01-05 13:23:34 ET More on Elevation Oncology Seeking Alpha’s Quant Rating on Elevation Oncology Historical earnings data for Elevation Oncology Financial information for Elevation Oncology For further details see: Elevation Oncology says its c...

2024-01-05 12:32:13 ET DENVER, Colo., Jan. 5, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Banzai International Inc (NASDAQ: BNZI), Dermata Therapeutics (NASDAQ: DRMA), Ainos Inc (NASDAQ: AIMD),...

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones PR Newswire -- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcin...

Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference PR Newswire BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective c...

2023-11-02 11:29:58 ET Elevation Oncology press release ( NASDAQ: ELEV ): Q3 GAAP EPS of -$0.25. As of September 30, 2023, Elevation Oncology had cash, cash equivalents and marketable securities totaling $94.8 million. Expects its existing cash, cash equivalents and ma...

Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements PR Newswire -- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary ...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Elevation Oncology Inc. (ELEV) is expected to report $-0.34 for Q3 2023

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and developmen...

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021 PR Newswire NEW YORK , Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of sele...